跳至主要内容
临床试验/NCT02075047
NCT02075047终止3 期

A PHASE 3, MULTICENTER, FOUR-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY TRIAL OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR I DISORDER (CURRENT OR MOST RECENT EPISODE MANIC)

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.50 个研究点 分布在 2 个国家目标入组 171 人开始时间: 2014年5月23日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
终止
发起方
入组人数
171
试验地点
50
主要终点
Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Week 4

研究概览

简要总结

The purpose of this study is to determine if ziprasidone is safe and effective for the treatment of children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
10 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • DSM V criteria for Bipolar I disorder (manic or mixed); age 10 - 17 years.

排除标准

  • Imminent risk of suicide or homicide, as judged by the site investigator; any history of serious or unstable medical illness, including risk for QT prolongation.

研究组 & 干预措施

1

Placebo Comparator

干预措施: placebo oral capsules (Drug)

ziprasidone

Experimental

干预措施: ziprasidone oral capsules (Drug)

结局指标

主要结局

Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Week 4

时间窗: Baseline, Week 4

YMRS: an 11-item scale that measured the severity of manic episodes. Four items (irritability, speech, thought content, and disruptive/ aggressive behavior) were rated on a scale from 0 (symptom absent) to 8 (symptom extremely severe). The remaining items were rated on a scale from 0 (symptom absent) to 4 (symptom extremely severe). YMRS total score was sum of score of all 11 items and ranged from 0 (no symptoms) to 60 (extreme severity of symptoms), higher score indicated higher severity of mania.

次要结局

  • Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score at Weeks 1, 2, 3, and 4(Baseline, Week 1, 2, 3, 4)
  • Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Weeks 1, 2, and 3(Baseline, Week 1, 2, 3)
  • Clinical Global Impression of Improvement (CGI-I) Scores at Weeks 1, 2, 3, and 4(Baseline, Week 1, 2, 3, 4)

研究者

发起方
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (50)

Loading locations...

相似试验

Efficacy and Safety Trial of Flexible Doses of Oral... | 临床试验